BioSpace News Archive

NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced the publication of long-term efficacy and safety data based on analyses at 109 weeks from the 192-week open-label extension trial of a Phase 2 study of VILTEPSO® (viltolarsen) injection in the Journal of Neuromuscular Diseases.

At a time when hospitals are under unprecedented logistical and financial strain, a new industry-wide report illuminates the potential for saving money and reducing waste and emissions by extending the life of “single-use” medical devices through reprocessing.

Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. Antonella Santuccione Chadha as Chief Medical Officer.

Recently, the Journal of Clinical Oncology (JCO, IF:44.544), an internationally renowned oncology journal, published an online paper on the AENEAS study of Ameile® (Aumolertinib Mesylate Tablets, an innovative drug developed by Hansoh Pharma), which was led by Professor Lu Shun of the Chest Hospital Affiliated to Shanghai Jiao Tong University.

Orphan drug designation applies to patients with primary mitochondrial myopathy due to nuclear DNA mutations (nPMM) in the NuPower Phase 3 clinical trial.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of sotagliflozin for the treatment of heart failure.

Extraordinary General Meeting of BAC’s shareholders postponed until June 3, 2022 , at 10:00 a.m., Eastern Time.

MiMedx Group, Inc., a transformational placental biologics company, announced receiving a $4.6 Million award to evaluate PURION® processed Dehydrated Human Amnion Chorion Membrane as an advanced treatment option for wound and burn care.

Axsome Therapeutics, Inc. today announced the publication on May 30, 2022 of the results from the pivotal GEMINI Phase 3 clinical trial of AXS-05 (dextromethorphan-bupropion) in major depressive disorder (MDD).

[31-May-2022] With strong support from the Government of Djibouti , this program will pilot a new Friendly™ mosquito control technology to combat the growing threat to the region posed by the rapidly spreading malaria vector, Anopheles stephensi.